The stock of Amneal Pharmaceuticals Inc (AMRX) has seen a 4.19% increase in the past week, with a 13.51% gain in the past month, and a 18.50% flourish in the past quarter. The volatility ratio for the week is 6.90%, and the volatility levels for the past 30 days are at 4.74% for AMRX. The simple moving average for the last 20 days is 9.79% for AMRX stock, with a simple moving average of 32.32% for the last 200 days.
Is It Worth Investing in Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Right Now?
Company’s 36-month beta value is 1.19.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AMRX is 102.52M, and currently, short sellers hold a 2.74% ratio of that floaft. The average trading volume of AMRX on May 10, 2024 was 1.65M shares.
AMRX) stock’s latest price update
The stock of Amneal Pharmaceuticals Inc (NASDAQ: AMRX) has decreased by -1.82 when compared to last closing price of 6.59. Despite this, the company has experienced a 4.19% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-03 that Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2024 Results Earnings Conference Call May 3, 2024 8:30 AM ET Company Participants Tony DiMeo – Head of Investor Relations Chirag Patel – President and Co-Chief Executive Officer Chintu Patel – Co-Chief Executive Officer Tasos Konidaris – Executive Vice President and Chief Financial Officer Joe Renda – Senior Vice President, Chief Commercial Officer, Specialty Conference Call Participants Nathan Rich – Goldman Sachs Leszek Sulewski – Truist Securities David Amsellem – Piper Sandler Balaji Prasad – Barclays Capital Chris Schott – J.P. Morgan Operator Good morning and welcome to Amneal Pharmaceuticals First Quarter 2024 Earnings Call.
Analysts’ Opinion of AMRX
Many brokerage firms have already submitted their reports for AMRX stocks, with RBC Capital Mkts repeating the rating for AMRX by listing it as a “Sector Perform.” The predicted price for AMRX in the upcoming period, according to RBC Capital Mkts is $5 based on the research report published on April 07, 2021 of the previous year 2021.
Goldman, on the other hand, stated in their research note that they expect to see AMRX reach a price target of $6.50, previously predicting the price at $4. The rating they have provided for AMRX stocks is “Buy” according to the report published on March 08th, 2021.
Guggenheim gave a rating of “Buy” to AMRX, setting the target price at $5.50 in the report published on December 14th of the previous year.
AMRX Trading at 11.51% from the 50-Day Moving Average
After a stumble in the market that brought AMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.23% of loss for the given period.
Volatility was left at 4.74%, however, over the last 30 days, the volatility rate increased by 6.90%, as shares surge +13.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.21% upper at present.
During the last 5 trading sessions, AMRX rose by +4.19%, which changed the moving average for the period of 200-days by +111.44% in comparison to the 20-day moving average, which settled at $5.93. In addition, Amneal Pharmaceuticals Inc saw 6.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMRX starting from BOYER ANDREW S, who sale 29,302 shares at the price of $4.13 back on Aug 11 ’23. After this action, BOYER ANDREW S now owns 244,739 shares of Amneal Pharmaceuticals Inc, valued at $120,921 using the latest closing price.
Stock Fundamentals for AMRX
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.35 for the gross margin
The net margin for Amneal Pharmaceuticals Inc stands at -0.07. The total capital return value is set at 0.06. Equity return is now at value -146.19, with -4.76 for asset returns.
Based on Amneal Pharmaceuticals Inc (AMRX), the company’s capital structure generated 1.03 points at debt to capital in total, while cash flow to debt ratio is standing at 0.08. The debt to equity ratio resting at -39.68. The interest coverage ratio of the stock is 1.66.
Currently, EBITDA for the company is 417.96 million with net debt to EBITDA at 8.03. When we switch over and look at the enterprise to sales, we see a ratio of 1.79. The receivables turnover for the company is 3.73for trailing twelve months and the total asset turnover is 0.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.65.
Conclusion
In a nutshell, Amneal Pharmaceuticals Inc (AMRX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
